Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants
with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal
junction (GEJ) who have not previously received systemic chemotherapy for this setting.
All eligible participants will receive the combination of cetuximab plus S-1 (a combination
of tegafur, gimeracil, and oteracil) and cisplatin.